For patients caught between diagnoses — showing features of both multiple sclerosis and neuromyelitis optica but testing negative for every known autoantibody — there has been no molecular explanation and no clear treatment path. A newly characterized autoantigen may begin to fill that gap, with implications for how autoimmune neurological diseases are classified and managed.
Researchers screened 297 patients with inflammatory autoimmune central nervous system diseases and identified four individuals whose serum contained immunoglobulin G antibodies targeting MLC1 (modulator of VRAC current 1), a membrane protein concentrated at astrocytic end feet — the cellular extensions that interface with blood vessels in the brain. All four MLC1 IgG-positive patients displayed a hybrid clinical picture, sharing overlapping but atypical features of both MS and NMOSD, and none tested positive for either the aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) antibodies that currently define known disease subtypes. Critically, a monoclonal MLC1 antibody reproduced disease-relevant pathology in mouse cerebellar slice cultures and triggered encephalitis in a rat model, establishing pathogenic plausibility beyond mere association.
This finding sits within a productive decade of autoantibody discovery in neuroimmunology — AQP4 antibodies were identified in 2004, MOG antibodies confirmed clinically significant around 2016 — and MLC1 appears to extend that lineage to astrocyte membrane physiology. The astrocytic end-foot localization of MLC1 is mechanistically coherent: end feet regulate blood-brain barrier integrity and ionic homeostasis, and their disruption has been implicated in edema and lesion formation in NMOSD. The study's most important limitation is scale — four seropositive patients is a very small discovery cohort, making prevalence estimates unreliable and leaving the full clinical spectrum poorly defined. The rodent data are encouraging but do not yet establish human dosing or inflammatory cascades. This is an early-stage, incremental-but-meaningful finding: it gives clinicians a new marker to test in seronegative patients and opens a mechanistically grounded research program, but significant replication in larger cohorts is needed before MLC1 testing enters diagnostic workflows.